Effect of lockdown periods on 7-day and 30-day survival compared to pre-pandemic period. by Youssef Hbid (18803761)

Bivariate analysis of predisposing factors associated with increased risk of death within 30 days. by Ingvar Ludwig Augusto de Souza (17854609)

“…<p>Bivariate analysis of predisposing factors associated with increased risk of death within 30 days.</p>…”

Adjusted hazard ratio for 30-day mortality demonstrating adjusted associations between SCAI shock stages with 30-day mortality. by Héctor González-Pacheco (4279714)

Subjects: “…stepwise significant increase…”

Cumulative distribution of the K6 total score using a 7-day versus 30-day recall period. by Miranda R. Chilver (17605055)

Cumulative distribution of the TTPN psychological distress item using a 7-day versus 30-day recall period. by Miranda R. Chilver (17605055)

Cumulative distribution of the K6 “feeling nervous” item using a 7-day versus 30-day recall period. by Miranda R. Chilver (17605055)

Independent predictors of 30-day mortality. by Jagdip Kang (18196537)

“…The mean duration of VA-ECMO support was 6 days (interquartile range 4–7 days). The 30-day mortality was 50.8%. …”

Histology of wound tissues at day 7and day 21. by Ayami Hasegawa-Haruki (18831138)

Subjects:

Angiogenesis observed in wound tissue at day 7 and day 21. by Ayami Hasegawa-Haruki (18831138)

Subjects:

A comparison of actual 7-day case totals and predicted 7-day cases totals for the ML+R_t methods. by Bradley S. Price (6441476)

Generalizable improvement of QOL measures on day 7 vs. infusion day. by Jordan K. Abbott (8934239)

Subjects:

Cumulative 7-day and 30-day lag effects for O₃ (per 10 ppb increase) and all mental health outcomes from 2005 through 2013 in California. by Angela-Maithy Nguyen (10521361)

Forest plot: Mortality (follow-up: 30 days). by David R. Soriano-Moreno (11060678)

“…</p><p>Results</p><p>We found 7 RCTs (n = 3053). The PS, compared to fibrinolysis alone, may have an important reduction on mortality (3.3% vs 3.9%; −5 per 1000; 95% CI: −16 to +10); and has an important reduction on reinfarction (2.6% vs 4.4%; −19 per 1000; 95% CI: −27 to −6), revascularization (9.0% vs 26.8%; −169 per 1000; 95% CI: −220 to −64), and recurrent ischemia (1.2% vs 5.7%; −46 per 1000; 95% CI: −52 to −27) at 30 days follow up. …”

Forest plot: Reinfarction (follow-up: 30 days). by David R. Soriano-Moreno (11060678)

“…</p><p>Results</p><p>We found 7 RCTs (n = 3053). The PS, compared to fibrinolysis alone, may have an important reduction on mortality (3.3% vs 3.9%; −5 per 1000; 95% CI: −16 to +10); and has an important reduction on reinfarction (2.6% vs 4.4%; −19 per 1000; 95% CI: −27 to −6), revascularization (9.0% vs 26.8%; −169 per 1000; 95% CI: −220 to −64), and recurrent ischemia (1.2% vs 5.7%; −46 per 1000; 95% CI: −52 to −27) at 30 days follow up. …”

Average 30-day all-cause HCRU and costs per PD infection. by Natalie Zarabi (11592337)

Subjects:

SCAI shock stages with corresponding 30-day mortality rate and discriminatory performance. by Héctor González-Pacheco (4279714)

Subjects: “…stepwise significant increase…”

PSA through primary toxicity endpoint (day 30). by Shyam Nyati (8435871)

Subjects:

Liver and spleen mass in sarcopenia-hyperammonemia modelling on Day 30. by Maria Nadinskaia (22662419)

Number of days between baseline and day 1. by Andrew T. Kosharek (22086368)

Subjects:

Patient severity and outcome by priority levels (day 7–10, saturation). by Nicolas Donat (15453396)